Mainz Biomed N.V (MYNZ) EBIAT: 2021-2023
Historic EBIAT for Mainz Biomed N.V (MYNZ) over the last 2 years, with Dec 2023 value amounting to -$5.2 million.
- Mainz Biomed N.V's EBIAT rose 36.70% to -$5.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$9.8 million, marking a year-over-year increase of 49.54%. This contributed to the annual value of -$21.7 million for FY2024, which is 17.66% up from last year.
- Per Mainz Biomed N.V's latest filing, its EBIAT stood at -$5.2 million for Q4 2023, which was up 17.72% from -$6.3 million recorded in Q3 2023.
- Mainz Biomed N.V's 5-year EBIAT high stood at $8.3 million for Q2 2023, and its period low was -$8.2 million during Q4 2022.
- In the last 3 years, Mainz Biomed N.V's EBIAT had a median value of -$5.6 million in 2022 and averaged -$3.2 million.
- As far as peak fluctuations go, Mainz Biomed N.V's EBIAT plummeted by 3,603.77% in 2022, and later skyrocketed by 18,465.32% in 2023.
- Quarterly analysis of 3 years shows Mainz Biomed N.V's EBIAT stood at $233,710 in 2021, then crashed by 3,603.77% to -$8.2 million in 2022, then spiked by 36.70% to -$5.2 million in 2023.
- Its EBIAT was -$5.2 million in Q4 2023, compared to -$6.3 million in Q3 2023 and $8.3 million in Q2 2023.